|
|
|
Summary
of 2003 CPCRA Posters and Presentations
| 2nd International AIDS Society Conference on Pathogenesis and Treatment, July 13-16, 2003, Paris, France |
Lawrence
J, Huppler Hullsiek K, Mayers D, Abrams D, Reisler R, Crane L, Schmetter
B, Dionne T, Saldanha J, Jones M, Baxter J. Failure of structured
treatment interruption (STI) to confer benefit in the setting of
treatment failure: CPCRA 064 results by baseline CD4 count and phenotypic
sensitivity score (PSS) subgroups. Oral presentation.
Loutfy
M, Walmsley S, Mullin C, Perez G, Neaton J. CD4+ cell increase to
highly active antiretroviral therapy (HAART) at one year is predictive
of clinical outcome despite incomplete viral suppression. Oral presentation.
MacArthur
RD, Chen L, Peng G, Novak R, van den Berg-Wolf M, Kozal M, Besch
L, Yurik T, Schmetter B, Henely C, Dehlinger M. Efficacy and Safety
of ABC+3TC versus ddI+d4T when Combined with a PI, NNRTI or Both
in AR-Naive Persons on Their First HAART Regimen: The NRTI Substudy
of the CPCRA 058 FIRST Study. Poster presentation.
| The American Thoracic Society - 99th International Conference, May 16-21, 2003, Seattle, WA |
Gordin
FM, Matts J, O'Brien R, Chaisson RE, Cohn D. Rifampin and Pyrazinamide
(RZ) is not Hepatotoxic in the Treatment of Latent Tuberculosis
Infection (LTBI) in HIV+ Persons. Abstract # 1667. Oral presentation.
| 10th Conference on Retroviruses and Opportunistic Infections, February 10-13, 2003, Boston, MA |
Lawrence
J, Mayers D, Huppler Hullsiek K, Collins G, Abrams D, Reisler RB,
Crane L, Schmetter B, Dionne T, Saldanha J, Jones M, Baxter J. CPCRA
064: A Randomized Trial Examining Structured Treatment Interruption
(STI) for Patients Failing Therapy with Multi-Drug Resistant (MDR)
HIV. Oral presentation.
El-Sadr
W, Neaton J, Neuhaus J, Gordin F. Comparison of Risk Factors for
Coronary Heart Disease Among Men and Women Enrolled in the SMART
Study. Poster presentation.
|
|
